PR 94273 

CINCINNATI, Jan. 28, 2022 /PRNewswire=KYODO JBN/ --

--New financing provides significant financial flexibility to propel growth

efforts, benefitting patients, providers, and pharma partners worldwide.

Enable Injections, Inc. ( https://enableinjections.com ) ("Enable"), a company

developing and manufacturing the enFuse(R) platform of investigational wearable

drug delivery systems, is pleased to announce $215 million in Series C

financing. Magnetar Capital ("Magnetar") led the financing along with new

institutional investments from GCM Grosvenor, Squarepoint Capital, Woody Creek

Capital Partners, and other investors. Enable received significant continued

support from existing investors including Cincinnati Children's Hospital

Medical Center, CincyTech, Cintrifuse, and Ohio Innovation Fund.

Photo – https://mma.prnewswire.com/media/1734916/Enable_Injections_enFuse.jpg

Logo – https://mma.prnewswire.com/media/962405/Enable_Injections_Logo.jpg

Enable Injections' enFuse(R) is an innovative drug delivery technology designed

to subcutaneously (SC) deliver large volumes of up to 50mL for a wide range of

therapies and diseases, and to provide patients and providers a safe,

convenient, and cost-effective alternative to IV administration. With improved

flexibility for patients and providers, enFuse is designed to enable an

increase in healthcare provider efficiencies, minimize patient exposure in the

clinic, and reduce healthcare costs, with the aim of benefiting patients and

healthcare providers worldwide.

"Enable Injections has seen a dramatic increase in demand for enFuse's

high-volume drug delivery technology. The funding from Magnetar will help

enFuse continue to redefine intravenous drug delivery by meaningfully scaling

our development and commercialization efforts. This will help us reach even

more patients who depend on intravenous medications and, we believe,

significantly improve their lives," said Mike Hooven, President and CEO, Enable

Injections. "Magnetar, and its healthcare team, bring valuable industry

expertise and an extensive network of financial and biotech contacts to Enable.

We are excited to partner with Magnetar to grow the enFuse platform globally

and achieve our shared vision of supporting next generation patient-healthcare

provider connections through an enhanced injection administration experience."

"This financing will provide additional resources to onboard important new

pharma partner programs and accelerate our commercialization programs and

platforms with existing pharma partners," said Tim Flaherty, EVP and CFO,

Enable Injections. "Enable is a stronger company with Magnetar as a strategic

partner, with its thoughtful approach to healthcare investing."

UBS Securities LLC served as exclusive placement agent to Enable Injections in

connection with this financing.

About Enable Injections:

Cincinnati-based Enable Injections is an investigational-stage company

developing and manufacturing on-body subcutaneous drug delivery systems

designed to improve the patient experience, support superior outcomes, and

advance healthcare system value and economics. Enable's body-worn enFuse(R)

drug delivery platform utilizes standard container closure systems to deliver

high-volume pharmaceutical and biologic therapeutics. For more information,

please visit www.enableinjections.com.

About Magnetar Capital:

Founded in 2005, Magnetar is a multi-strategy alternative investment manager

with approximately $13.5 billion of assets under management as of September 30,

2021. Magnetar seeks to achieve stable risk-adjusted returns by

opportunistically employing a wide-range of alternative credit and fixed

income, energy and infrastructure, and systematic investing strategies.

Magnetar invests across regions and business structures, in both public and

private markets, taking advantage of the deep rigor of fundamental and

quantitative analysis. The firm is based in Evanston, Illinois, with additional

offices in London and Houston. For more information, visit www.magnetar.com.

SOURCE: Enable Injections, Inc.

CONTACT: Jennifer Estep, Enable Injections, 513-326-2800,

jestep@enableinjections.com